Abstract 1408P
Background
PDT using the novel photosensitizer DVDMS has shown promising activity in treating esophageal stenosis and improving dysphagia in local recurrent or metastatic EC in phase II study previously, with an esophageal stenosis overall response rate (es-ORR) of 40% at day 28 under a 102 J/cm light dose at 24-hour intervals. This phase IIIb trial aims to further assess the efficacy and safety of DVDMS-mediated PDT.
Methods
This trial enrolled patients with previously treated advanced EC, with a Stooler dysphagia grade ≥ 2 (CTR20221271). Patients were randomized 2:1 to receive DVDMS-mediated PDT (DVDMS of 0.2 mg/kg, light dose of 102 J/cm, PDT delivered at 630±5 nm 24±2 hours intervals) or treatment of physician’s choice, including chemotherapy and best supportive care. The primary endpoint was es-ORR.
Results
As of December 31, 2023, 84 eligible pts had completed the day 28 follow-up or censored. At day 28, the DVDMS-PDT group (n=56) exhibited an es-ORR of 48.21% (95% CI: 34.66-61.97), significantly higher than the control group's 3.57% (95% CI: 0.09-18.35, P < 0.0001). Average esophageal diameter increases were 1.76 mm and -0.67 mm. Other endpoints are detailed in the table. Treatment-emergent adverse events occurred in 80.36% of the DVDMS-PDT group and 92.86% of controls. Phototoxicity was negative in 75% patients in DVDMS-PDT group on day 7, increasing to 94.64% by day 28. Two deaths related to adverse events in the DVDMS-PDT group (one possibly treatment-related) and four in the control group.
Conclusions
Preliminary results indicates that DVDMS-mediated PDT has significant higher es-ORR and improves dysphagia as well as quality of life with a favorable safety profile compared with treatment of physician’s choice, emphasizes this new option for advanced EC with dysphagia. The trial is ongoing. Table: 1408P
| Outcomes on day 28 | DVDMS PDT (n=56) | Treatment of physician’s choice (n=28) |
| Reduction at least 1 grade in Stooler's dysphagia grade, n (%) | 18 (32.14) | 0 |
| Mean change from baseline in Stooler's dysphagia score | -0.4 | 0.1 |
| Mean change from baseline in EORTC QLQ-C30 overall health score (Higher scores indicate better overall health) | 3.442 | -1.471 |
| Mean change from baseline in EORTC QLQ-OES18 dysphagia score (Higher scores indicate more severe symptoms) | -3.140 | 0.000 |
| Mean change from baseline in EORTC QLQ-OES18 eating score (Higher scores indicate more severe symptoms) | -10.145 | -3.431 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Guangsheng Pharmaceutical Co., Ltd.
Funding
Shanghai Guangsheng Pharmaceutical Co., Ltd.
Disclosure
S. Zhang: Financial Interests, Personal and Institutional, Affiliate: Shanghai Guangsheng Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
498P - Report of 9 cases of embryonal tumours of the central nervous system with multilayered rosettes (ETMR)
Presenter: Ruyu Ai
Session: Poster session 17
Resources:
Abstract
499TiP - A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Presenter: Brian Stockdale
Session: Poster session 17
500TiP - Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Presenter: Michael Weller
Session: Poster session 17
501TiP - Clinical performance evaluation of a brain cancer liquid biopsy
Presenter: James Cameron
Session: Poster session 17
692P - Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study
Presenter: Yaroslav Zhulikov
Session: Poster session 17
693P - Causes of death in patients with malignant adrenal tumors: A population-based analysis
Presenter: Shangqing Ren
Session: Poster session 17
946P - Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
Presenter: Jung Sun Kim
Session: Poster session 17
948P - Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort study
Presenter: Jia-Yong Su
Session: Poster session 17
Resources:
Abstract
949P - Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
Presenter: Xianhai Mao
Session: Poster session 17
950P - Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Poster session 17